Business Context and Reporting Period
This Form 8-K was filed by Dandrit Biotech USA, Inc. on November 9, 2016. The filing reports the entry into a material definitive agreement: the Second Amendment to an Asset Purchase Agreement originally dated April 4, 2016, between Dandrit Biotech USA, Inc. and OncoSynergy Inc.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the legal terms of the amended agreement.
Material Changes
The Second Amendment waives several conditions previously required to close the asset purchase transaction, which must occur before December 31, 2016. The waived conditions include:
- The requirement for Dandrit Biotech USA, Inc. to obtain stockholder votes to consummate the transaction.
- The requirement to demonstrate satisfaction of listing requirements for uplisting to a national stock exchange, including effecting a reverse stock split.
- The requirement to change the company's name.
Guidance, Outlook, and Risks
Management commentary is limited to the execution of the amendment to facilitate the closing of the asset purchase. The filing does not provide forward-looking guidance, specific risk factors, or details on contingencies beyond the terms of the agreement. The transaction closing deadline remains December 31, 2016, unless otherwise determined by the parties.
Investor Verification Checklist
- Verify the full text of the Second Amendment (Exhibit 10.1) for any undisclosed terms.
- Confirm the status of the asset purchase closing relative to the December 31, 2016 deadline.
- Review the original April 4, 2016 Asset Purchase Agreement to understand the baseline terms being amended.
- Check subsequent filings for updates on the transaction status or any new conditions imposed.